Clinical outcomes of endoscopic submucosal dissection for superficial circumferential esophageal squamous cell carcinoma.


Journal

Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 05 06 2022
revised: 06 09 2022
accepted: 23 09 2022
pubmed: 14 10 2022
medline: 25 1 2023
entrez: 13 10 2022
Statut: ppublish

Résumé

Our aim was to elucidate the clinical outcomes of endoscopic submucosal dissection (ESD) for superficial circumferential esophageal squamous cell carcinoma (cESCC). Consecutive patients who underwent ESD for cESCC between 2009 and 2020 were retrospectively reviewed. Short-term outcomes were en-bloc resection, R0 resection, procedure time, and adverse events, whereas long-term outcomes were overall survival (OS), disease-specific survival (DSS), cumulative recurrence rate (CRR), and clinical course. Fifty-two patients with 52 cESCCs (median tumor length, 5.0 cm; interquartile range [IQR], 4.0-6.3) were evaluated. The en-bloc resection and R0 resection rates were 100% (95% confidence interval [CI], 94.4-100) and 69.2% (95% CI, 54.9-81.3), respectively. The median procedure time was 112 minutes (IQR, 87-162). Intraoperative perforations and delayed bleeding occurred in 4 (7.7%) and 1 (1.9%) patients, respectively. Among the 42 patients who underwent ESD alone, 36 (85.7%) experienced esophageal strictures. Within a median follow-up of 49.1 months (IQR, 25.7-74.7), the 4-year OS, DSS, and CRR were 86.2% (95% CI, 71.6-93.6), 95.5% (95% CI, 83.1-98.9), and 11.5% (95% CI, 4.1-23.1), respectively. There was no significant difference in the OS between patients with low-risk cESCC (pT1a, negative lymphovascular invasion, and negative vertical margin) and high-risk lesions, regardless of undergoing additional treatment (P = .93). In 31 patients with low-risk cESCC who were treated with ESD alone, the 4-year OS, DSS, and CRR were 93.2%, 100%, and 0%, respectively. ESD is a highly curative treatment for cESCC with favorable long-term outcomes, especially in low-risk patients. Stricture-prevention techniques should be improved to optimize the benefits of ESD for cESCC.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Our aim was to elucidate the clinical outcomes of endoscopic submucosal dissection (ESD) for superficial circumferential esophageal squamous cell carcinoma (cESCC).
METHODS METHODS
Consecutive patients who underwent ESD for cESCC between 2009 and 2020 were retrospectively reviewed. Short-term outcomes were en-bloc resection, R0 resection, procedure time, and adverse events, whereas long-term outcomes were overall survival (OS), disease-specific survival (DSS), cumulative recurrence rate (CRR), and clinical course.
RESULTS RESULTS
Fifty-two patients with 52 cESCCs (median tumor length, 5.0 cm; interquartile range [IQR], 4.0-6.3) were evaluated. The en-bloc resection and R0 resection rates were 100% (95% confidence interval [CI], 94.4-100) and 69.2% (95% CI, 54.9-81.3), respectively. The median procedure time was 112 minutes (IQR, 87-162). Intraoperative perforations and delayed bleeding occurred in 4 (7.7%) and 1 (1.9%) patients, respectively. Among the 42 patients who underwent ESD alone, 36 (85.7%) experienced esophageal strictures. Within a median follow-up of 49.1 months (IQR, 25.7-74.7), the 4-year OS, DSS, and CRR were 86.2% (95% CI, 71.6-93.6), 95.5% (95% CI, 83.1-98.9), and 11.5% (95% CI, 4.1-23.1), respectively. There was no significant difference in the OS between patients with low-risk cESCC (pT1a, negative lymphovascular invasion, and negative vertical margin) and high-risk lesions, regardless of undergoing additional treatment (P = .93). In 31 patients with low-risk cESCC who were treated with ESD alone, the 4-year OS, DSS, and CRR were 93.2%, 100%, and 0%, respectively.
CONCLUSIONS CONCLUSIONS
ESD is a highly curative treatment for cESCC with favorable long-term outcomes, especially in low-risk patients. Stricture-prevention techniques should be improved to optimize the benefits of ESD for cESCC.

Identifiants

pubmed: 36228694
pii: S0016-5107(22)02035-1
doi: 10.1016/j.gie.2022.09.027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

232-240.e4

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Auteurs

Tatsunori Minamide (T)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Noboru Kawata (N)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Yuki Maeda (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Masao Yoshida (M)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Yoichi Yamamoto (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kazunori Takada (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Yoshihiro Kishida (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Sayo Ito (S)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kenichiro Imai (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kinichi Hotta (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Junya Sato (J)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hirotoshi Ishiwatari (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroyuki Matsubayashi (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroyuki Ono (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH